Conference Reports

Chicago, Illinois, US
10 November 2018 - 12 November 2018
San Diego, California, US
21 September 2018 - 25 September 2018
Bangkok, Thailand
28 September 2018 - 01 October 2018
Munich
25 August 2018 - 29 August 2018
Barcelona
18 March 2018 - 20 March 2018
Orlando, Florida
10 March 2018 - 12 March 2018
Los Angeles, California, US
24 January 2018 - 26 January 2018
Abu Dhabi
04 December 2017 - 08 December 2017
Anaheim, California, US
11 November 2017 - 15 November 2017
Singapore
20 October 2017 - 21 October 2017
Singapore
06 October 2017 - 08 October 2017
Barcelona
26 August 2017 - 30 August 2017
Singapore
13 July 2017 - 15 July 2017
San Diego, California, US
09 June 2017 - 13 June 2017
Houston, Texas, US
22 February 2017 - 24 February 2017
12 November 2016 - 16 November 2016
Yangon
14 October 2016 - 16 October 2016
Rome
27 August 2016 - 31 August 2016
Mexico City
04 June 2016 - 07 June 2016
New Orleans, Louisiana
10 June 2016 - 14 June 2016
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 13 Sep 2018

In patients diagnosed with atrial fibrillation (AF), late initiation of oral anticoagulant (OAC) therapy is common and is associated with a significantly increased risk of stroke, according to a study led by the Chinese University of Hong Kong (CUHK).

16 Apr 2016
New drug applications approved by US FDA as of 1 - 15 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Christina Lau, 07 Sep 2018

Treatment with rivaroxaban for 45 days after hospital discharge reduces symptomatic venous thromboembolism (VTE), but not VTE-related mortality, in medically ill patients, results of the MARINER trial have shown.

Pearl Toh, 20 Sep 2018
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.